argenx SE (ARGX) Bundle
Argenx Discontinues Phase 3 UplighTED Study for Thyroid Eye Disease
Argenx SE (NASDAQ:ARGX) announced on Dec 18, 2025, the discontinuation of its Phase 3 UplighTED studies for efgartigimod subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED). The decision was made following a recommendation from an Independent Data Monitoring Committee (IDMC) that cited futility during an interim analysis.
The UplighTED studies were designed to evaluate the efficacy and safety of efgartigimod PH20 SC, focusing on proptosis and patient quality of life. While the safety profile of the therapy remained favorable, the committee determined the trial was unlikely to meet its primary endpoints. Chief Medical Officer Luc Truyen, M.D., Ph.D., stated the company is disappointed by the outcome but noted the futility analysis allows for the responsible management of resources.
Argenx remains focused on its portfolio of antibody-based medicines and its approved FcRn blocker, VYVGART, which is marketed globally for other autoimmune conditions. The company plans to conduct a full analysis of the trial data to inform future research. Further details on the company mission and history are available at ARGX-history-mission-ownership and ARGX-mission-vision.
Financial and market performance data for Argenx SE include:
- Current share price: $849.52 USD, representing a decrease of 3.2%.
- Intraday trading range: $827.52 to $853.96 USD.
- Market capitalization: Approximately $51.96 billion USD.
- Trading volume: 488,913 shares.
- Analyst price target: $1,248 USD, indicating a potential upside of 40.3%.
Over the past 12 months, the stock has traded between a low of $510.06 and a high of $934.62 USD. Investors can find more detailed financial analysis at ARGX-financial-health and ARGX-investor-profile.
argenx SE (ARGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.